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Abstract
Background: It is presumed that pharmacological and non-pharmacological treatment of prenatal common mental
disorders can mitigate associated adverse effects in offspring, yet strong evidence for the prophylactic benefits of
treatment is lacking. We therefore examined the effect of prenatal treatments for common mental disorders on
offspring outcomes.
Methods: For this meta-analysis, articles published up to August 31, 2017, were obtained from PubMed, PsycInfo,
Embase, and Cochrane databases. Included studies needed to be randomized controlled trials (RCTs) on the effect
of treatment of prenatal common mental disorders comparing an intervention to a control condition, including
offspring outcome(s). Random effects models were used to calculate Hedges’ g in the program Comprehensive
Meta-Analysis© (version 3.0).
Results: Sixteen randomized controlled trials among 2778 pregnant women compared offspring outcomes between
prenatal interventions and control groups. There were zero pharmacological, 13 psychological, and three other
interventions (homeopathy, relaxation interventions, and short psycho-education). Birth weight (mean difference
42.88 g, g = 0.08, 95% CI −0.06 to 0.22, p = 0.27, n = 11), Apgar scores (g = 0.13, 95% CI −0.28 to 0.54, p = 0.53,
n = 4), and gestational age (g = 0.03, 95% CI −0.06 to 0.54, p = 0.49, n = 10) were not significantly affected. Other
offspring outcomes could not be meta-analyzed due to the inconsistent reporting of offspring outcomes and
an insufficient number of studies.
Conclusions: Non-pharmacological interventions had no significant effect on birth outcomes, although this
outcome should be considered with caution due to the risk of biases. No randomized controlled trial examined the
effects of prenatal pharmacological treatments as compared to treatment as usual for common mental disorders on
offspring outcomes. Present clinical guidelines may require more research evidence on offspring outcomes, including
child development, in order to warrant the current recommendation to routinely screen and subsequently
treat prenatal common mental disorders.
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Background
Leading clinical guidelines advise to screen and treat
common mental disorders and symptoms among all
pregnant women [1, 2]. Common mental disorders and
symptoms generally refer to mood and anxiety disorders,
including depression, phobias (including extreme fear of
childbirth ‘tokophobia’), generalized anxiety disorder,
post-traumatic stress disorder, and obsessive-compulsive
disorders [2]. Prevalence rates of mental disorders dur-
ing pregnancy are estimated as high as 12.4% for mood
disorders and 15.2% for anxiety disorders [3, 4]. Next to
the burden of these common mental disorders for the
pregnant women, these disorders may be harmful for
the offspring [5]. Adverse effects on the offspring include
almost 20% increased odds of low birth weight as com-
pared to offspring from mothers without mental prob-
lems [6]. Low birth weight in turn has repeatedly been
linked to negative (long term) somatic outcomes such as
all-cause mortality, stunted growth, respiratory prob-
lems, and obesity [7]. In addition, low birth weight is as-
sociated with an increased risk for the development of
mental problems [8]. Other adverse effects of prenatal
mental disorders on the (unborn) child include a 13% in-
creased risk of premature birth [6] and lower Apgar
scores [5]. Similar to the effects of low birth weight, chil-
dren from women who had a mental disorder during
pregnancy have a two to three times increased risk for
the development of psychopathology [9]. This includes
an increased risk of symptoms of depression in (late)
adolescence [10], an increased risk of anxiety in the ages
6 to 9 years old, and internalizing and externalizing (psy-
chiatric) problems at the ages 2 to 6 [2, 11, 12]. Other
risks for the offspring of pregnant women with common
mental disorders include behavioral, motor, developmen-
tal, and cognitive problems such as attention-deficit
hyperactivity disorder and an atypical (functional and
structural) brain development [2, 9, 13, 14]. Theoretical
accounts of the associations between prenatal mental
health and offspring outcomes focus on a cascade of
processes, such as activation of the stress-response
(hypothalamic-pituitary-adrenal [HPA] axis), (epi)genet-
ics, e.g., methylation of “stress” genes, elevated levels of
intrauterine cytokines or glucocorticoids, and poor
self-care during pregnancy (e.g., smoking, disturbed ap-
petite) or poor mother-child attachment in the postpar-
tum period due to the disabling nature of mental health
problems [10, 14–18].
Effective treatments for prenatal common mental dis-
orders are therefore of paramount importance given the
recurrent and life-long course of most mental disorders
and their association with (chronic) somatic conditions
[19]. Although the exact mechanisms through which pre-
natal mental disorders exert an effect on offspring are cur-
rently unknown, the adverse outcomes themselves are
clear. Current evidence-based treatments for mental disor-
ders during pregnancy, i.e., medication and/or psycho-
logical interventions, are (implicitly) presumed to not only
address mental needs of pregnant women, but also to con-
fer prophylactic mental and physical benefits for offspring
[20, 21]. As implied in the NICE guidelines, “The impact of
any mental health problem may often require more urgent
intervention than would usually be the case because of its
potential effect on the foetus/baby (..)” [2]. The most used
treatment for these disorders during pregnancy is anti-
depressant medication (AD; 3.7% of all pregnant women in
the UK up to 6.2% in the USA [22, 23]), followed by psy-
chological therapies including cognitive behavioral therapy
(CBT) [24]. Supporting evidence for the benefits of these
treatments is however limited, and the impact is typically
restricted to the pregnant woman [1, 2, 24, 25]. Previous
meta-analyses indicate that the evidence is restricted to psy-
chological interventions for prenatal depression, for which
CBT and interpersonal psychotherapy were shown to be
most effective [24].
Given that the recommended treatments for prenatal
common mental disorders might paradoxically have an
adverse effect on the offspring intrauterine, it is crucial
to examine the effects of prenatal maternal treatments
on offspring. To our knowledge, no meta-analyses of
randomized controlled trials (RCTs) have examined the
effect of various treatments on common mental disor-
ders during pregnancy on offspring [1, 2, 24, 25]. One
meta-analysis indicated a positive, but small effect of
prenatal preventive and acute treatments for depression
on child functioning only [26]. Nonetheless, no conclu-
sions regarding the effect of acute treatment for prenatal
common mental disorders on offspring could be made,
given that the majority of the studies that were included
in this review included healthy pregnant women without
(a history of ) MDD or depressive symptoms (not acute
treatment). Moreover, in the review, the authors did not
assess the effects of acute treatment alone on child func-
tioning. The last is the main aim of this meta-analysis,
i.e., to examine the effect of prenatal treatments for
common mental disorders on offspring outcomes. Some
studies furthermore report adverse effects of prenatal
antidepressants use on preterm birth, birth weight, and
Apgar scores [27], persistent pulmonary hypertension
(PPHN) [28, 29], development [30, 31], and cardiovascu-
lar malformations [32] in offspring. However, these re-
ports are derived from non-randomized studies that do
not permit conclusions of causality. The beneficial or
possibly iatrogenic effects of psychological interventions
on offspring are however less clear, despite the beneficial
effects of psychotherapies for perinatal major depressive
disorders as reported in previous meta-analyses [24, 25].
A review of the evidence from RCTs is timely and war-
ranted. The primary aim of the current study was to
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conduct a meta-analysis to examine whether treatments
for pregnant women with common mental disorders, as
recommended in leading clinical guidelines (including
antidepressants and psychotherapy) [1, 2], prevent ad-
verse effects in offspring, both in terms of somatic and
mental outcomes.
Method
Search strategy and selection criteria
This meta-analysis was conducted in accordance with
the PRISMA guidelines and registered on PROSPERO
[33]. A search in PubMed, PsycInfo, Embase, and the
Cochrane database of randomized trials was performed
on articles published from their origin through April
2016 and updated up to August 31, 2017. Five search
strings were composed using standardized vocabulary
(e.g., MeSH terms and text words), terms for searching
title and abstract, and Boolean operators. The full search
string is presented in Additional file 1. The five key
strings targeted pregnancy, common mental disorders,
interventions, offspring outcomes, and study design.
Included studies needed to (1) be a (cluster) randomized
controlled trial; (2) treat (3) one or more prenatal com-
mon mental disorders or high levels of symptoms; (4)
compare an intervention to a control condition; (5) in-
clude at least one offspring outcome; and (6) report suffi-
cient information to calculate effect sizes (or provide this
information available upon request). Included common
mental disorders and symptoms were mood disorders and
anxiety disorders according to the definition of DSM-IV
axis I and older [34]. These included obsessive-compulsive
disorders and trauma- and stress-related disorders/symp-
toms. Severe mental illnesses like bipolar disorder, psych-
osis, schizophrenia, or substance abuse were excluded due
to the low prevalence rates [2]. The common mental dis-
order or symptoms could be assessed by self-report mea-
sures or clinical interviews, provided that the participants
were primarily selected based upon the presence of mental
disorders or high symptom levels. The control condition
was defined as care or treatment as usual, wait-list control,
or placebo medication. Language was restricted to English
and Dutch due to the language proficiency of the authors.
Two authors (MEB and SG) independently screened and
selected the articles and assessed the risk of bias using the
seven criteria as proposed by the Cochrane Handbook for
Systematic Reviews of Interventions. Disagreement was
solved by consultation of a third rater (CLB) and reaching
consensus. The Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) framework
[35] was used to assess the overall level of certainty and
strength of evidence for each of the main offspring out-
comes. The evidence for each of the main offspring out-
comes was potentially downgraded based upon risk of
bias, inconsistency, indirectness, imprecision, number of
participants, and pooled effect sizes.
Offspring outcome measures
The primary outcomes included all offspring variables
collected in the neonatal period, during infancy and
early childhood. They included Apgar scores, birth
weight, gestational age, and measures of cognitive,
motor, and emotional development. Examples of these
variables are offspring depressive and anxiety symptoms
(e.g., as assessed by the strengths and difficulties ques-
tionnaire [36]), general development (e.g., Bayley scales
of infant development [37]), child behavior (e.g., child
behavior checklist [38]), neurodevelopmental problems
(e.g., Brazelton neonatal behaviour assessment scale
[39]), and biological measures (e.g., cortisol levels,
height, weight). No restrictions were made on the assess-
ment instruments (self-report, reports, observations).
Offspring outcomes needed to be reported as continuous
outcomes in order to be able to calculate Hedges’ g ef-
fect sizes. Where applicable, these outcomes were con-
verted to the international system of units (SI), or to
equal units (e.g., months to weeks, days to weeks, kilo-
grams to grams). Data was extracted by one author (SG)
using a standardized form and fully checked by a second
author (MEB). Offspring measures that were reported in
less than three studies were excluded from analyses.
Data analysis
The effect sizes for all child outcomes were calculated
using Hedges’ g and 95% confidence intervals (CI) to cor-
rect for small sample bias. Each effect size thus indicates a
standardized comparison between the intervention group
and control group. To calculate the pooled effect sizes, we
extracted the reported mean scores, standard deviations,
and number of participants for each group (intervention
and control groups separately) for each offspring measure-
ment. The software program Comprehensive Meta-Ana-
lysis© (version 3.0) was used to calculate pooled effect
sizes, mean differences, forest plots, heterogeneity, and
funnel plots. The effect sizes were interpreted according
to Cohen’s rule of thumb (small = 0.20–0.49; medium=
0.50–0.79; large = 0.80 and higher). As an indicator of het-
erogeneity among the effect sizes, we used the I2 statistics
(0% = no heterogeneity to 75% = high heterogeneity). We
calculated 95% confidence intervals [40] around I2, using
the non-central χ2-based approach within the heterogi
module for Stata [41]. Funnel plots were used to visually
inspect for publication bias, which was statistically
checked with Egger’s test of the intercept and Duval and
Tweedie’s trim and fill procedure [42].
A priori, we expected substantial heterogeneity be-
tween studies and therefore used a random effects
model [43] in which a pooled effect size was calculated
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for each offspring outcome, and one random effects
model for the overall pooled effect size. Secondly, several
post hoc subgroup analyses were performed, in which
pooled effect sizes were calculated for the main DSM
disorders or symptoms, DSM disorders or symptoms
and the offspring outcomes, type of intervention
(psychotherapy, supplements or medication, and other),
diagnostic status (through clinical interview or self-re-
ported symptoms), risk of bias (high, low), and whether
the author indicated a significant and positive effect of
the intervention on maternal main DSM disorders or
symptoms (yes, no). A mixed effects model was used in
the subgroup analyses, where the pooled effect sizes
within subgroups were calculated with the random ef-
fects model, and the fixed effects model was used to test
the difference between subgroups.
Results
The search yielded 10,160 results up to April 2016. Cita-
tions and references of included articles and 207 reviews
resulted in 129 additional articles. The search was
updated up to August 2017, which resulted in 968
additional articles. A total of 9770 articles were screened
after removal of duplicates. The systematic search
resulted in 18 eligible articles (0.18%; see Fig. 1 for full
details) reporting results of 16 RCTs, which are reported
in Table 1. In total, 2778 pregnant women were random-
ized over 11 different treatment types. Treatment types
included (variations of ) CBT, massage therapy, psycho-
education, relaxation treatments, and couples therapy.
Intensity of the interventions ranged from two psycho-
education phone sessions up to 16 CBT-based home
visits. Details of treatment type, intensity, and the effects
on maternal psychopathology are reported in Table 1.
Seven studies focused on depression only [44–50], two
on both depression and anxiety [51, 52], three on anxiety
only [53–55], two on fear of childbirth [56, 57], one on
posttraumatic stress disorder (PTSD) [58], one on stress
in general [59], and one on various common mental dis-
orders [60]. The risk of bias in the included studies was
in general high, as reported in Table 1.
The included studies reported 28 different offspring
outcome measures. Most outcomes were reported in a
single study only. Analyses were restricted to the out-
comes that were reported in at least three studies, which
resulted in three eligible outcomes: birth weight, Apgar
(1, 5, and 10 min combined), and gestational age (Fig. 2).
For five studies, it was therefore not possible to aggre-
gate any of the reported offspring outcomes in the
meta-analysis, both in terms of target outcome (e.g., cog-
nitive vs. emotional development) and measurement in-
strument. Effect sizes of the removed outcomes for each
study are reported in Fig. 3. The mean values for each
included study, and the overall highest and lowest values
on the three offspring outcomes are displayed in Table 2.
Since there were no RCTs of pharmacological inter-
ventions during pregnancy reporting offspring outcomes,
data from 11 non-pharmacological RCTs (reported in 13
articles) were analyzed. First, pooled effect sizes for each
selected outcome were calculated. Outcomes of the
meta-analysis are reported in Table 3 and displayed in
Fig. 2. Birth weight was not significantly affected by in-
terventions as compared to control conditions, corre-
sponding to a mean difference of 42.88 g (95% CI −
33.06 to 118.83, N = 11, n = 1583, I2 = 39% [45, 47, 49,
50, 52–55, 57, 59, 60]) between the intervention and
control groups. Gestational age and Apgar scores did
not significantly improve or worsen by prenatal inter-
ventions (gestational age mean difference = 0.08 weeks
[95% CI −0.09 to 0.24], N = 10, n = 1669, I2 = 0% [49, 50,
52, 53, 55–57, 59, 60]; Apgar mean difference = 0.21
[95% CI −0.28 to 0.71], N = 4, n = 663, I2 = 68% [51, 52,
55, 57]). The pooled effect size indicated an overall
non-significant effect on Apgar scores, birth weight, and
gestational age together. Since these three offspring out-
comes are heterogeneous in interpretation, this overall
result is not further discussed. Heterogeneity across the
outcomes was low, I2 = 23% (95% CI 0–60%). There was
some indication of publication bias, as indicated by
Duval and Tweedie’s trim and fill procedure (studies
trimmed = 2, adjusted g = 0.05, 95% CI −0.05 to 0.15).
Visual inspection of the funnel plot and the Egger’s test
(p = 0.16) did not indicate publication bias. The evidence
for each of the three pooled effect sizes was downgraded
using the GRADE assessment to very low certainty of
evidence. For each of the outcomes, there was a serious
risk of bias, consistency in measures, serious indirect-
ness, and serious imprecision. Birth weight and gesta-
tional age were rated as important outcomes, and Apgar
scores were rated as not important.
Table 3 displays several subgroup analyses. Studies tar-
geting depression and anxiety, or with a focus on other
disorders, did not show a significant pooled effect size,
hence did not improve offspring outcomes based on the
three selected outcomes. According to the mixed effects
analysis, the subgroups did not differ significantly. When
investigating the separate offspring outcomes for each
disorder (depression, anxiety, and other), it appeared
that there was no significant effect of intervention on
offspring outcomes within each disorder. The overall ef-
fect size in the risk of bias subgroup analysis was not
significant. Although studies with a high risk of bias
were significantly related to positive birth outcomes (g =
0.21, 95% CI 0.00 to 0.42, p = 0.05, N = 7, n = 786, I2 =
31% [45, 47, 51, 53, 55, 57, 59]), the mixed effects ana-
lysis indicated no significant difference between high
and low risk of bias studies (p = 0.09). The method
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through which the (possible) diagnosis was established,
i.e., through clinical interview or self-report, whether the
authors reported that the intervention had a significant
effect on treating maternal common mental disorder
(symptoms) compared to the control group, and the type
of intervention (psychotherapy versus other types), did
not significantly affect offspring outcomes, nor did the
mixed effects analyses show differences between the sub-
groups (Table 3).
Discussion
Leading international clinical guidelines [1, 2] recom-
mend screening and treatment of pregnant women for
mental disorders and symptoms, with the clinical view
to additionally prevent adverse effects on the offspring.
The systematic search identified 16 non-pharmacological
RCTs, including 14 psychological interventions that re-
ported offspring outcomes. The results from the current
meta-analysis indicate that non-pharmacological inter-
ventions do not have a significant effect on improving
birth outcomes, and their effects could not be
meta-analyzed for (developmental) offspring outcomes.
Therefore, based on the current evidence, there is no
strong indication of prophylactic effects. Although no
statistically significant result was obtained for birth
weight, all effect sizes within the 95% confidence interval
around the pooled effect estimate were small, indicating
that the true effect of prenatal interventions on birth
weight is most likely small. Furthermore, the quality of
most studies was low and the studies were relatively het-
erogeneous. An explanation for the non-significant effect
size may be a ceiling effect since offspring in the control
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and intervention groups had a birth weight within the
normal range. The birth weight in the trials ranged from
2883 to 3626 g, indicating there was no low birth weight
according to the worldwide standards for low birth
weight, that is less than 2500 g [61].
Secondly, the meta-analysis did not show that the
somatic outcomes indexed by Apgar scores and gesta-
tional age were significantly associated with the
non-pharmacological interventions. As for birth weight,
the confidence intervals around the pooled effect esti-
mates for Apgar scores and gestational age indicate that
a true effect is most likely small. It was furthermore not
possible to investigate the impact of prenatal interven-
tions on preventing preterm birth, since the included
studies had different definitions of preterm birth (differ-
ent gestational age), or did not report enough informa-
tion to calculate effect sizes. Additionally, five out of 16
studies reported different measures of (long term) off-
spring outcomes. It was therefore not possible to investi-
gate the effects of interventions on non-somatic
outcomes, such as psychopathology or developmental
problems. Although previous research and clinical
Chambers, 2009 Anxiety -0.64 -1.48 0.20 0.14
Karamoozian, 2015 Mixed 1.04 0.28 1.80 0.01
Rouhe, 2013 Fear of childbirth 0.15 -0.19 0.49 0.37
Verbeek, 2016 Mixed 0.00 -0.25 0.25 1.00
0.13 -0.28 0.54 0.53Apgar, pooled
Bastani, 2006 Anxiety 0.52 0.13 0.91 0.01
Cappon, 2015 Anxiety 0.04 -0.42 0.49 0.87
Chambers, 2009 Anxiety -0.52 -1.34 0.30 0.21
Field, 2009 Depression 0.22 -0.11 0.54 0.19
Milgrom, 2015 Depression 0.07 -0.57 0.71 0.83
Netsi, 2015 Depression 0.34 -0.43 1.11 0.39
Rothberg, 1991 Stress 0.15 -0.27 0.57 0.49
Rouhe, 2013 Fear of childbirth 0.09 -0.13 0.30 0.42
Verbeek, 2016 Mixed -0.09 -0.34 0.16 0.48
Vilhena, 2017 Common mental health 0.23 -0.10 0.57 0.17
Zhao, 2017 Depression -0.18 -0.39 0.03 0.10
0.08 -0.06 0.22 0.27BW, pooled
Bastani, 2006 Anxiety 0.00 -0.38 0.38 1.00
Chambers, 2009 Anxiety -0.54 -1.36 0.29 0.20
Fenwick, 2015 Fear of childbirth 0.03 -0.26 0.32 0.85
Field, 2009 Depression 0.22 -0.11 0.54 0.19
Milgrom, 2015 Depression 0.00 -0.68 0.68 1.00
Rothberg, 1991 Stress 0.14 -0.28 0.56 0.52
Rouhe, 2013 Fear of childbirth 0.06 -0.15 0.28 0.56
Verbeek, 2016 Mixed -0.12 -0.38 0.13 0.33
Vilhena, 2017 Common mental health 0.27 -0.07 0.61 0.11
Zhao, 2017 Depression -0.02 -0.23 0.19 0.82
0.03 -0.06 0.13 0.49
-1.00 0.00 1.00
GA, pooled
Author, year Study focus g and 95% CIg
95% CI
p-valueLower - Upper
Fig. 2 Forest plots for Apgar scores, birth weight, and gestational age. BW = birth weight, GA = gestational age, g = Hedges’ g, mixed = combination
of multiple common mental disorders and/or symptoms
Behavioral outcomes
Milgrom, 2015 Depression Combined 9 months 0.42 -0.30 1.15 0.25
Field, 2009 Depression Combined 1 day 0.41 0.09 0.74 0.01
Verbeek, 2016b Mixed Combined 18 months -0.05 -0.35 0.24 0.71
Cappon, 2015 Anxiety Combined 2-3 months 1.49 0.97 2.01 0.00
Netsi, 2015 Depression Combined 2 months -0.57 -1.35 0.21 0.15
Field, 2009 Depression Cortisol levels 0 1.04 0.69 1.39 0.00
Maselko, 2015 Depression Combined 7 years -0.07 -0.23 0.09 0.41
Rahman, 2008 Depression Combined Combined 0.14 -0.01 0.28 0.06
Rothberg, 1991 Stress Length 0 -0.28 -0.70 0.14 0.19
Rouhe, 2013 Fear of childbirthCombined 0 -0.04 -0.34 0.26 0.79
Urizar, 2011 Risk of PPD Combined Combined 0.19 -0.36 0.74 0.50
Biological outcomes
Social/ developmental / emotional outcomes
Madigan, 2015 PTSD ASSP Disorg. 12 months -0.07 -0.82 0.67 0.85
Maselko, 2015 Depression Combined 7 years -0.06 -0.22 0.10 0.45
Milgrom, 2015 Depression Combined 9 months 0.58 -0.14 1.31 0.12
Netsi, 2015 Depression Difficult temp. 2 months 0.08 -0.68 0.84 0.83
Urizar, 2011 Risk of PPD Combined 18 months -0.21 -0.78 0.36 0.48
Verbeek, 2016b Mixed Combined 18 months -0.10 -0.40 0.20 0.51
Verbeek, 2016b Mixed BSID Cognitive 18 months -0.14 -0.43 0.15 0.35
-1.00 0.00 1.00 2.00
Cognitive outcomes
Author, year Study focus g and 95% CIg p-valueOutcome measure Timing
95% CI
Lower - Upper
Fig. 3 Forest plots of excluded offspring outcomes. g = Hedges’ g, mixed = combination of multiple common mental disorders and/or symptoms,
combined = combination of multiple offspring outcomes and/or timing of offspring outcomes, PPD = peripartum depression, ASSP
Disorg = Ainsworth stranger situation disorganized attachment measure, BSID Cognitive = Bayley scales of infant development-cognitive
subscale, difficult temp = difficult temperament
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guidelines [1, 2] report on harmful effects of prenatal
mental disorders on offspring, including an increased
risk of low birth weight [6], the current meta-analysis
could not support the notion that treatment can mitigate
this effect. Furthermore, the current results did not indi-
cate that pregnant women in the care as usual or pla-
cebo groups had worse or better offspring outcomes.
This is to some extent in contrast to a recent
meta-analysis, in which it was concluded that prenatal
preventive and acute interventions for MDD (symptoms)
improved overall child functioning. This effect was how-
ever primarily based upon preventive interventions and
offspring behaviour [26].
The current meta-analysis found zero RCTs on the ef-
fects of antenatal treatment of common mental disor-
ders with medication (i.e., antidepressants) on offspring.
This is noteworthy given the fact that antidepressant
medication is one of the most used treatments during
pregnancy [22]. Furthermore, previous reviews of
non-randomized trials indicate an association between
prenatal antidepressant use and adverse offspring out-
comes, including lower birth weight, preterm birth,
lower Apgar scores [27, 62], and cardiovascular malfor-
mations [32]. Correspondingly, untreated maternal men-
tal disorders has been associated with similar adverse
effects, which in turn are linked to other subsequent
Table 2 Study offspring outcomes
Author, year Mean birth weight (Sd.) in grams Mean Apgar score (Sd.) Mean gestational age (Sd.) in weeks
Bastani, 2006 [53] IG, 3168 (420)
CG, 2883 (640)
n/a IG, 38 (5.9)
CG, 38 (4.4)
Cappon, 2015 [54] IG, 3366 (523)
CG, 3344 (773)
n/a n/a
Chambers, 2009 [55] IG, 3232 (695)
CG, 3562 (529)
IG, Apgar 1 min: 7.8 (1.3)
CG, Apgar 1 min: 8 (1.1)
IG, Apgar 5 min: 8.5 (0.7)
CG, Apgar 5 min: 9.1 (0.3)
IG, 38.4 (2.5)
CG, 39.5 (1.4)
Fenwick, 2015 [56] n/a n/a IG, 39.2 (1.6)
CG, 39.1 (2.0)
Field, 2009 [45] IG, 3318 (360)
CG, 3226 (492)
n/a IG, 39 (1.2)
CG, 38.7 (1.6)
Karamoozian, 2015 [51] n/a IG, Apgar 1 min: 8.9 (0.3)
CG, Apgar 1 min: 8.1 (0.8)
IG, Apgar 5 min: 9.7 (0.5)
CG, Apgar 5 min: 9.3 (0.7)
n/a
Milgrom, 2015 [50] IG, 3626 (786)
CG, 3575 (595)
n/a IG, 40 (1)
CG, 40 (2)
Netsi, 2015 [47] IG, 3423 (503)
CG, 3180 (871)
n/a n/a
Rothberg, 1991 [59] IG, 3214 (649)
CG, 3113 (690)
n/a IG, 38.7 (3)
CG, 38.3 (2.7)
Rouhe, 2013 [57] IG, 3532 (550)
CG, 3486 (518)
IG, Apgar 1 min: 8.7 (1.1)
CG, Apgar 1 min: 8.5 (1.4)
IG, Apgar 5 min: 9.3 (1.0)
CG, Apgar 5 min: 9.1 (1.2)
IG, Apgar 10 min: 9.7 (0.8)
CG, Apgar 10 min: 9.5 (0.9)
IG, 39.7 (1.5)
CG, 39.6 (1.6)
Verbeek, 2016; Verbeek,
2016b [52]
IG, 3419 (651)
CG, 3474 (561)
IG, Apgar 1 min: 8.6 (n/a)
CG, Apgar 1 min: 8.6 (n/a)
IG, Apgar 5 min: 9.5 (n/a)
CG, Apgar 5 min: 9.5 (n/a)
IG, Apgar 10 min: 9.8 (n/a)
CG, Apgar 10 min: 9.8 (n/a)
IG, 38.9 (2.3)
CG, 39.2 (1.8)
Vilhena, 2017 [60] IG, 3390 (440)
CG, 3270 (560)
n/a IG, 39.4 (1.2)
CG, 38.9 (1.9)
Zhao, 2017 [49] IG, 3256 (522)
CG, 3349 (529)
n/a n/a
Combined range per
offspring outcome
Lowest value, 2883
Highest value, 3626
Lowest value, 7.8
Highest value, 9.8
Lowest value, 38
Highest value, 40
IG intervention group, CG control group
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offspring problems [7]. Other studies suggest that the ef-
fects of antidepressants on offspring might be minimal
[63–65]. Due to the nature of the studies (non-rando-
mized cohort trials), there is insufficient evidence of the
possible effects of prenatal antidepressant usage. It is
therefore not clear what the net effects of antidepres-
sants are for offspring. RCTs and comparative treatment
trials are needed to disentangle whether these offspring
outcomes are related to antidepressant use or are pre-
dominantly the result of the mental disorders of the
mother. To estimate the (enduring) relative effects of
pharmacological and non-pharmacological interventions
on offspring, a RCT comparing the two intervention
types may provide more information on the prophylactic
effects on offspring. Such design would be more ethical
since the pregnant woman receives treatment according
to clinical recommendations. Moreover, it would provide
more information on the effects of antidepressants.
Collectively, the findings of the meta-analysis indicate
that there is insufficient data to support the beneficial ef-
fects of prenatal treatments on offspring and that more
research on the effects of prenatal treatments on off-
spring is needed. These results of the meta-analysis must
be interpreted in the context of some limitations. In gen-
eral, the included trials had a high risk of bias and re-
ported different offspring outcomes, and the GRADE
assessment indicated very low certainty of evidence,
thereby limiting the results. Overall, there is some indi-
cation that non-pharmacological interventions may have
a positive influence on offspring birth weight; however,
the effect was not significant and could be overestimated
due to the small samples sizes and high risk of bias. The
small sample size of pregnant women, and the small
amount of included studies, increases the risk of
false-positive and false-negative birth outcomes. Further-
more, other birth outcomes including preterm birth, low
birthweight for gestational age, or child development
could not be analyzed due to the inconsistent reporting
and lack of studies. There is no conclusive evidence that
interventions aimed to target prenatal mental disorders
are beneficial or iatrogenic for offspring, especially with
regard to long-term and psychological impact.
Table 3 Meta-analyses and subgroup analyses results
N No. of participants g 95% CI p I2 95% CI pa
Effect of prenatal interventions
on offspring outcomes (BW,
GA, Apgar)
All studies [45, 47, 49–57, 59, 60] 13 1796 0.09 − 0.03 to 0.21 0.14 23 0–60
Effect of prenatal interventions
for each offspring outcome
BW [45, 47, 49, 50, 52–55, 57, 59] 11 1583 0.08 − 0.06 to 0.22 0.27 39 0–70
GA [49, 50, 52, 53, 55–57, 59, 60] 10 1669 0.03 − 0.06 to 0.13 0.49 0 0–53
Apgar [51, 52, 55, 57] 4 663 0.13 − 0.28 to 0.54 0.53 68 0–87
Subgroup analyses
Type of diagnosis* Anxiety [52–57] 6 852 − 0.01 − 0.22 to 0.20 0.89 40 0–75 0.41
BW [52–55, 57] 5 668 0 − 0.33 to 0.32 1 70 22–88
GA [52–56] 5 779 − 0.06 − 0.24 to 0.12 0.54 27 0–71
Depression [45, 47–50] 5 575 0.02 − 0.15 to 0.18 0.86 0 0–79
BW [45, 47–50] 5 575 0.01 − 0.20 to 0.23 0.90 22 0–68
GA [45, 48–50] 4 550 0.05 − 0.12 to 0.21 0.58 0 0–85
Other [51, 52, 59, 60] 4 283 0.22 − 0.90 to 0.54 0.17 62 0–85
BW [52, 59, 60] 3 254 0.06 − 0.15 to 0.27 0.57 22 0–97
GA [52, 59, 60] 3 254 0.07 − 0.19 to 0.33 0.60 45 0–84
Risk of bias High [45, 47, 51, 53, 55, 57, 59] 7 786 0.21 − 0.00 to 0.42 0.05 31 0–70 0.09
Low [49, 50, 52, 54, 56, 60] 6 1010 − 0.00 − 0.13 to 0.12 0.97 0 0–61
Diagnosis through clinical
interview or self-report
Clinical interview [45, 47, 50] 3 203 0.20 − 0.07 to 0.47 0.15 0 0–90 0.43
Self-report [49, 51–60] 10 1593 0.08 − 0.06 to 0.22 0.28 36 0–70
Type of intervention Psychotherapy [47, 49–52, 57, 59] 7 1130 0.08 − 0.10 to 0.27 0.40 39 0–75 0.67
Other [45, 53–56, 60] 6 666 0.13 − 0.02 to 0.28 0.09 0 0–74
Report of sign. Effect of
intervention on mother?
No [52, 55, 59, 60] 4 483 0.05 − 0.18 to 0.28 0.68 31 0–75 0.64
Yes [45, 47, 49–51, 53, 54, 56, 57] 9 1313 0.11 − 0.04 to 0.26 0.14 29 0–67
aThe p value indicates whether the subgroups differ from each other. g = Hedges’ g, 95% CI = confidence interval 95% of Hedges’ g. *In this subgroup analysis,
the Verbeek 2016 study subgroups depression, anxiety, and combined (other) were analyzed separately. BW birth weight, GA gestational age. Superscript numbers
refer to included studies in each analysis
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For health care professionals, there is little evidence
that prenatal non-pharmacological interventions are
beneficial for the offspring with respect to birth weight,
gestational age, and Apgar scores. There is not enough
support that commonly used treatments for prenatal
mental disorders are beneficial to offspring and hence
do not provide a scientific foundation to support recom-
mendations of specific treatment options with respect to
the benefit for the child. More systematic research with
long-term follow-up of the offspring is consequently
needed to support (inter)national guidelines for prenatal
mental disorders. As a first step, research on prenatal in-
terventions may register birth outcomes from birth re-
ports of (former) participants in RCTs. RCTs focusing
on pharmacological interventions as compared to psy-
chotherapy during pregnancy are needed, even though
this may be challenging due to ethical considerations
and preferences of pregnant women and their health
care providers.
Conclusions
The results from the current meta-analysis indicate no
significant effects of non-pharmacological interventions
on improving birth outcomes. No firm conclusion of
prophylactic effects can be drawn due to the reported
limitations. Despite the recommendation of leading
international clinical guidelines [1, 2] to routinely screen
pregnant women for common mental disorders and
symptoms, and subsequently treat the mother to reduce
perinatal symptomatology and prevent adverse effects on
the offspring, there is insufficient data to support the
clinical recommendation regarding the safety of prenatal
treatments for the offspring. Prior research implies that
prenatal interventions improve maternal psychopath-
ology [24, 26], yet more research is warranted to draw
stronger conclusions on the impact of prenatal interven-
tions on offspring, especially regarding child develop-
ment. Potential adverse effects on offspring cannot be
ruled out, thereby underscoring the urgent need for
properly controlled trials to best inform care approaches
for mothers and their offspring.
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